Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S1-S3

  Korth Bradley, Joan ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MONOCLONAL ANTIBODY; PEPTIDE; BIOLOGICAL PRODUCT; BISPECIFIC ANTIBODY;

ANTIBODY PRODUCTION; BIOTECHNOLOGY; BLOOD GROUP TYPING; CLINICAL PHARMACOLOGY; DIABETES MELLITUS; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG MONITORING; IMMUNOGENICITY; NOTE; PANCREAS ISLET; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; ANIMAL; HUMAN;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; PEPTIDES; PHARMACOLOGY, CLINICAL;

EID: 84923365555     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.463     Document Type: Note

References (15)

1. Riedel S,. Edward Jenner and the history of smallpox and vaccination. BUMC Proc. 2005; 18: 21-25.
2. Roth J, Qureshi S, Whitford I, et al. Insulin's discovery: new insights on its ninetieth birthday. Diabetes Metab Res Rev. 2012; 28: 293-304.
3. Norman DJ,. Mechanisms of action and overview of OKT3. Therap Drug Monit. 1995; 17: 615-620.
4. Aldeghaither D, Smaglo B, Weiner L,. Beyond peptides and mAbs-current status and future perspective of biotherapeutics with novel constructs. J Clin Pharm. 2015; 55 (3 Suppl): S4-S20.
5. Rathi C, Meibohm B,. Clinical pharmacology of bispecific antibody constructs. J Clin Pharm. 2015; 55 (3 Suppl): S21-S28.
6. Glassman P, Abuqayyas L, Balthasar J,. Assessment of antibody biodistribution. J Clin Pharm. 2015; 55 (3 Suppl): S29-S38.
7. Vande Casteele N, Gils A,. Pharmacokinetics of atni-TNF monoclonal antibodies in inflammatory bowel-disease: adding value to current practice. J Clin Pharm. 2015; 55 (3 Suppl): S39-S50.
8. Mould D, Dubinsky M,. Dashboard systems: pharmacokinetic/pharmacodynamics mediate dose optimization. J Clin Pharm. 2015; 55 (3 Suppl): S51-S59.
9. Xu Z, Zhou H,. Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharm. 2015; 55 (3 Suppl): S60-S74.
10. Zheng S, McIntosh T, Wang W,. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development-opportunities and challenges. J Clin Pharm. 2015; 55 (3 Suppl): S75-S84.
11. Perez Ruixo JJ, Doshi S, Sohn W, Chow A,. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors. J Clin Pharm. 2015; 55 (3 Suppl): S85-S92.
12. Alemayehu D, Utt E, Knirsch C,. Vaccines: a review of immune-based interventions to prevent and treat disease. J Clin Pharm. 2015; 55 (3 Suppl): S93-S102.
13. Zhang Y, Wei X, Bajaj G, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharm. 2015; 55 (3 Suppl): S103-S115.
14. Damle B, White R, Wang H,. Considerations for clinical pharmacology studies for biologics in emerging markets. J Clin Pharm. 2015; 55 (3 Suppl): S116-S122.
15. Scott B, Klein A, Wang J,. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinical relevant differences and indication extrapolation. J Clin Pharm. 2015; 55 (3 Suppl): S123-S132.